Condition: ADPKD · Sponsor: University Medical Center Groningen
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.
This description comes directly from the study's public registry record.
Dr. E Meijer · +31 50 3616161 · esther.meijer@umcg.nl
T. Bais, MD · t.bais@umcg.nl
Always discuss trial participation with your own doctor first.
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| University Hospital Leuven | Leuven, Belgium | Recruiting |
| Hospital La Cavale Blanche | Brest, France | Recruiting |
| Necker-Enfants Malades Hospital | Paris, France | Recruiting |
| Charité University Hospital | Berlin, Germany | Recruiting |
| University Hospital Cologne | Cologne, Germany | Recruiting |
| Med. Klinik und Poliklinik III, Universitätsklinikum Dresden. | Dresden, Germany | Recruiting |
| Amsterdam University Medical Center | Amsterdam, Netherlands | Recruiting |
| University Medical Center Groningen | Groningen, Netherlands | Recruiting |
| Erasmus University Medical Center | Rotterdam, Netherlands | Recruiting |
| Fundación Puigvert | Barcelona, Spain | Recruiting |
| La Fundación Jiménez Díaz | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05373264